BioLife Solutions Announces Repligen Merger; Employee Video Circulated

What Happened

• BioLife Solutions, Inc. confirmed its July 21, 2026 Agreement and Plan of Merger with Repligen Corporation. Under the agreement, Merger Sub 1 will merge into BioLife (First Merger) and then the surviving BioLife will merge into Merger Sub 2 (Second Merger), resulting in BioLife becoming a wholly owned subsidiary of Repligen, subject to the conditions in the merger agreement.
• On August 3, 2026 BioLife management circulated an email to employees containing a Repligen-recorded video providing additional information about Repligen and the pending mergers; a transcript of that video and the circulating email were furnished as exhibits to the Form 8-K.

Key Details

• Merger agreement date: July 21, 2026; employee communication date: August 3, 2026.
• Transaction structure: two-step merger (Merger Sub 1 into BioLife, then surviving BioLife into Merger Sub 2) with Repligen as ultimate parent.
• Repligen will file a registration statement on Form S-4 containing the proxy statement/prospectus; a definitive proxy/prospectus will be mailed to BioLife stockholders when final.
• The filing includes standard forward-looking statements and cautions about risks (regulatory approvals, stockholder approval, integration risks, potential litigation, and other factors).

Why It Matters

• This 8-K provides a corporate update on a material transaction that would make BioLife a wholly owned subsidiary of Repligen if completed. Investors should note the deal remains subject to customary closing conditions, regulatory and stockholder approvals, and other risks.
• Next actionable items for investors: monitor the Form S-4/proxy statement filing, review the proxy when mailed, and consider the potential timing and effects of the merger (including any dilution from Repligen shares and integration-related risks) before making voting or investment decisions.